• LAST PRICE
    0.6011
  • TODAY'S CHANGE (%)
    Trending Down-0.0189 (-3.0484%)
  • Bid / Lots
    0.6011/ 10
  • Ask / Lots
    0.6098/ 2
  • Open / Previous Close
    0.6300 / 0.6200
  • Day Range
    Low 0.6011
    High 0.6500
  • 52 Week Range
    Low 0.5528
    High 2.5300
  • Volume
    115,785
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.62
TimeVolumeBLRX
09:32 ET17270.6016
09:38 ET37800.6069
09:45 ET2800.607001
09:57 ET10000.6199
09:59 ET3000.615
10:08 ET3000.615
10:10 ET3000.61501
10:26 ET10000.6198
10:28 ET15200.6152
10:33 ET11000.6152
10:44 ET2500.615
11:08 ET22000.6108
11:09 ET18000.6149
11:11 ET21300.6154
11:13 ET18000.6155
11:15 ET22700.6155
11:22 ET107030.6109
11:26 ET13000.64
11:38 ET3220.6109
11:40 ET4000.6109
11:42 ET4000.6109
11:49 ET1000.63298
11:51 ET3000.6156
11:54 ET1000.62
11:58 ET67180.6156
12:00 ET31000.6111
12:02 ET219000.6107
12:03 ET10000.6154
12:05 ET183990.6015
12:09 ET167000.6015
12:12 ET110000.6011
12:14 ET217230.6001
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBLRX
BioLine RX Ltd
51.4M
-0.6x
---
United StatesDYAI
Dyadic International Inc
53.8M
-6.8x
---
United StatesKRON
Kronos Bio Inc
60.1M
-0.5x
---
United StatesPTN
Palatin Technologies Inc
32.9M
-0.8x
---
United StatesKZR
Kezar Life Sciences Inc
56.2M
-0.5x
---
United StatesEVGN
Evogene Ltd
37.4M
-1.6x
---
As of 2024-05-23

Company Information

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact Information

Headquarters
Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
Phone
---
Fax
---

Executives

Chairman of the Board
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President - Development
Ella Sorani
Vice President-Clinical & Medical Affairs
Abi Vainstein-Haras

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$51.4M
Revenue (TTM)
$4.8M
Shares Outstanding
79.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.49
EPS
$-0.95
Book Value
$0.18
P/E Ratio
-0.6x
Price/Sales (TTM)
10.7
Price/Cash Flow (TTM)
---
Operating Margin
-1,035.29%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.